R. Meier

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy.

Blasko, J. Blasko, J. Sylvester, 2001, International journal of radiation oncology, biology, physics.

Five-year Biochemical Control Rates for Stereotactic Body Radiation Therapy for Organ-confined Prostate Cancer: A Multi-institutional Pooled Analysis

R. Meier, J. Aronovitz, C. King, 2012 .

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer

A. Kishan, I. Kaplan, R. Meier, 2019, JAMA network open.

The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States.

J. Sylvester, W. Cavanagh, R. Meier, 2001, Urology.

Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series

A. Kishan, I. Kaplan, R. Meier, 2021, Advances in radiation oncology.

Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience.

J. Blasko, J. Sylvester, P. Grimm, 2003, International journal of radiation oncology, biology, physics.

Fifteen year follow up of the first cohort of localized prostate cancer patients treated with brachytherapy.

J. Blasko, J. Sylvester, P. Grimm, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.

D. Brachman, I. Kaplan, R. Meier, 2018, International journal of radiation oncology, biology, physics.